Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Kirsten rat sarcoma virus oncogene homolog (KRAS) mRNA 3'-untranslated region (3'-UTR) is an extensive regulatory sequence, approximately 4.5 kilobases in length, that plays a pivotal role in the post-transcriptional control of the KRAS oncogene. It contains a multitude of cis-acting elements, including binding sites for microRNAs (miRNAs) such as the let-7 family and miR-185, as well as various RNA-binding proteins like HuR and AGO2. These interactions are essential for maintaining appropriate KRAS expression levels by regulating mRNA stability and translation. Genetic variations within this region, such as the rs61764370 single nucleotide polymorphism (SNP), can disrupt miRNA-mediated repression, leading to elevated KRAS protein levels and increased susceptibility to various cancers, including lung, colorectal, and pancreatic adenocarcinomas. Consequently, the KRAS mRNA 3'-UTR has emerged as a significant therapeutic target for RNA-based strategies, including miRNA mimics and antisense oligonucleotides (ASOs), designed to silence the oncogene or restore regulatory balance. By targeting the mRNA regulatory machinery, these approaches aim to overcome the historical challenges associated with directly inhibiting the KRAS protein.
RNA interference (RNAi), RNase H-mediated mRNA degradation, translational repression, and competitive inhibition of microRNA binding sites.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Kirsten rat sarcoma virus oncogene homolog mRNA 3'-untranslated region (KRAS mRNA 3'-UTR).